Sarepta Therapeutics, Inc.
Sarepta Therapeutics develops RNA-targeted therapeutics and gene therapies for rare diseases. They offer several treatments for Duchenne muscular dystrophy (DMD), including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS. The company is also developing SRP-5051 and SRP-9003 for DMD.
Overview
Strengths
- Current Price to Earnings Ratio (8.36) is lower than the sector mean (91.15).
- Price to book ratio (1.29) is lower than the sector mean (24.44).
- EV/EBITDA (6.80) is lower than the sector mean (85.60).
- EV/EBIT (7.91) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
Key Financial Data
| Indicator | Value |
|---|
| PER | 8.6 |
| EV/EBITDA | 7.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.7 |